Diligence memo · auto-generated · as of July 2, 2026
Prevail Therapeutics Inc.
Prevail Therapeutics Inc. looks fair against its niche peers and is dormant on financing cadence.
Businessfiled
Prevail Therapeutics Inc. operates in Pharma, based in NEW YORK.
Sub-sector tags: pharma.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Prevail Therapeutics Inc. has raised $57M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Series C (a $40M–$100M round).
Largest single filing: $57M on 2018-03-07.
Most recent recorded round closed around 2018-03-07.
Valuation (modeled)modeled
Provath models Prevail Therapeutics Inc. at approximately $2.0B (range $185M–$5.3B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 1.25× the median modeled value of Series C Pharma companies in 2016–2018 (5 peers) — value vs value, same stage and era. Within the normal band (125% of peer median) for its niche.
Financing rhythm & timingmixed
Last raise 8.3 yr ago; this sector typically re-raises about every 16 months.
Only one round on record and long silent — often defunct, acquired, or gone quiet.
Comparablesmixed
Capital scale ranks ahead of 86% of Pharma peers (310 compared).
Modeled value ranks above 94% of those peers.
Closest niche peers: Celsius Therapeutics, Inc., Akero Therapeutics, Inc., Advanced Cardiac Therapeutics Inc, Ovid Therapeutics Inc..
Peoplefiled
4 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.